English
 |
VAvi GP
| Quantity: | |
|---|---|
Target Application: Formulated exclusively for breeder geese prior to their egg-laying cycle.
Core Biological Agent: Utilizes the highly effective duck-embryo-adapted attenuated GD strain.
Delivery Method: Designed for seamless intramuscular injection in large-scale agricultural settings.
Physical Format: Engineered as a premium lyophilized mass for instantaneous reconstitution.
Commercial Supply: Manufactured by a leading global supplier, ensuring reliable, high-volume availability for commercial procurement.
The Gosling Plague Vaccine, Live (Strain GD) represents a critical advancement in preventative veterinary medicine, specifically tailored for the rigorous demands of commercial avian operations. Upon visual inspection, this premium vaccine presents as a distinct, spongy loose mass securely housed within a sterile glass vial. This meticulously engineered lyophilized texture is designed to detach effortlessly from the vial wall, facilitating an exceptionally smooth and immediate dissolution the moment physiological saline is introduced. The resulting solution is perfectly uniform and clear, ensuring seamless passage through standard veterinary injection equipment without any resistance or needle clogging.
By administering this live attenuated vaccine to mature breeder geese prior to their egg-laying cycle, agricultural managers establish a powerful, biological shield of maternal antibodies. This strategic intervention completely bypasses the stressful need to directly vaccinate fragile, newly hatched birds, instead transferring robust passive immunity directly through the egg yolk. The exhaustive manufacturing process guarantees that every single vial maintains consistent biological integrity and peak viral titer. This empowers commercial farming enterprises to proactively safeguard their extensive flocks against devastating viral outbreaks, thereby maintaining streamlined operational workflows and protecting their long-term agricultural investments.
| Category | Veterinary Non-prescription Drugs |
| [Veterinary Drug Name] | Generic Name: Gosling Plague Vaccine, Live (Strain GD) Trade Name: VAvi GP |
| [Composition] | This product contains Gosling Plague virus duck-embryo-adapted attenuated GD strain. Virus titer ≥10 3.0 ELD 50 per dose. |
| [Character] | Spongy loose mass, which detaches easily from the vial wall and dissolves rapidly after adding diluent. |
| [Function and Purpose] | For the prevention of Gosling Plague. Administered to breeder geese before egg-laying, providing immunity to goslings hatched from eggs laid within 21–270 days post-vaccination. |
| [Administration and Dosage] | Intramuscular injection. Dilute according to the bottle label’s indicated dose, using physiological saline. Vaccinate breeder geese 20–30 days before egg-laying. 1.0 ml (containing 1 dose) per goose. |
| [Precautions] | (1) This product is prohibited for use in goslings. (2) Store diluted vaccine in a cool, dark place and use up within 4 hours.(3) Disinfect the injection site prior to vaccination.(4) Properly dispose of used vials, equipment, and unused vaccine. |
| [Specification] | (1) 50 doses/vial, (2) 100 doses/vial, (3) 200 doses/vial |
| [Storage and Shelf Life] | Store below -15℃. Shelf life is 12 months. |
| [Manufacturer] | Qingdao Vland Animal Health Group Co., Ltd. |
| Usage Note | To be used only under veterinary supervision. |
Optimizing flock health requires biological solutions that are both highly effective and operationally efficient. This vaccine is engineered to deliver superior performance in the field.
Exceptional Dissolution Rate: The carefully freeze-dried, spongy loose mass instantly interacts with the diluent, creating a smooth, clump-free liquid that drastically accelerates the preparation process for field veterinarians during mass inoculation events.
Precision Dosage Delivery: Formulated to glide effortlessly through standard syringes, this product minimizes physical strain on administrators and ensures every single bird receives the exact required biological volume without equipment malfunctions.
Extended Passive Shielding: By focusing entirely on the maternal lineage, this preventative solution guarantees that offspring are born with a pre-established defense system, significantly reducing early-stage mortality rates in vulnerable hatchlings.
Strategic Waste Reduction: Available in multiple precise dose counts per vial, allowing facility managers to accurately match vaccine preparation volumes to their daily operational capacity, thereby eliminating costly biological waste.
Protecting newly hatched birds from devastating viral outbreaks requires a proactive, scientifically proven approach. This specialized live vaccine is meticulously engineered for administration to breeder geese prior to their egg-laying cycle.
Strategic Passive Defense: By inoculating the maternal lineage, exceptionally high levels of protective antibodies are seamlessly transferred directly into the egg yolk, completely bypassing the need to handle and stress fragile day-old hatchlings.
Extended Protection Window: The robust immunity generated by this formulation effectively shields offspring hatched from eggs laid between 21 and 270 days post-vaccination, covering the most critical and vulnerable stages of their early development.
Mortality Reduction: Gosling Plague is notorious for causing catastrophic mortality rates in unprotected young flocks. This maternal antibody transfer acts as an immediate biological firewall, significantly reducing early-stage fatalities and preserving the economic viability of large-scale agricultural investments.
The biological foundation of any effective immunization program lies in the purity and potency of its viral strain. We utilize a highly refined, rigorously tested biological agent to ensure maximum field efficacy.
Optimized GD Strain: Formulated using the proprietary duck-embryo-adapted attenuated GD strain, this product delivers exceptional immunogenicity without compromising the overall health, feed conversion, or egg production capacity of the mature breeding stock.
Guaranteed High Titer: Every single dose is strictly standardized to contain a virus titer of ≥10 3.0 ELD 50. This high concentration ensures a powerful, immediate immune response, leading to sustained and elevated antibody levels circulating within the maternal bloodstream.
Long-Lasting Efficacy: The precise attenuation process guarantees that the resulting immune defense is not only potent but incredibly durable, maintaining consistent biological protection throughout the designated laying cycle and ensuring uniform immunity across successive hatches.
Efficiency during mass inoculation events is paramount for commercial farm managers and field veterinarians. The physical characteristics of this vaccine are specifically engineered to streamline the preparation and administration process.
Advanced Lyophilization Texture: The vaccine presents as a distinct, spongy loose mass inside the glass vial. This unique freeze-dried structure is designed to detach effortlessly from the vial wall upon the introduction of a diluent.
Instantaneous Reconstitution: When mixed with standard physiological saline, the highly porous nature of the mass allows for rapid, complete dissolution within seconds. This eliminates tedious shaking or waiting periods, allowing veterinary teams to maintain a swift, uninterrupted operational pace.
Smooth Injection Dynamics: The resulting liquid is perfectly uniform and completely free of particulate clumps, ensuring it glides seamlessly through standard intramuscular injection needles. This prevents equipment blockages and minimizes tissue trauma at the injection site.
Managing biological resources effectively requires flexible packaging solutions that align with varying flock sizes and daily operational capacities. Our packaging strategy is designed to maximize utility while aggressively minimizing biological waste.
Versatile Dose Configurations: Available in precise 50, 100, and 200 doses per vial specifications. This variety allows procurement managers to accurately match their inventory to the specific daily inoculation targets of different breeding houses.
Optimized for Time-Sensitive Use: Because the reconstituted live vaccine must be entirely consumed within a strict 4-hour window, offering smaller and medium-sized vials prevents the costly disposal of unused, expired liquid that often occurs with oversized bulk packaging.
Lower Cost Per Bird: By virtually eliminating post-dilution waste and ensuring exact dosage delivery, commercial agricultural enterprises can significantly drive down the overall cost of their preventative health programs, maximizing the return on their biological investments.
Maintaining strict biological safety and adhering to precise administrative guidelines is crucial for the success of any commercial immunization strategy. This product comes with clear, rigorous protocols to safeguard your breeding stock.
Targeted Application Safety: The formulation is strictly prohibited for direct use in young goslings. It is exclusively calibrated for the mature immune systems of breeder geese 20 to 30 days prior to egg-laying, ensuring optimal antibody generation without adverse reactions.
Hygienic Administration Standards: To prevent secondary bacterial infections, the protocol mandates thorough disinfection of the intramuscular injection site prior to administration, aligning with the highest standards of modern veterinary biosecurity.
Responsible Waste Management: Comprehensive guidelines are provided for the proper disposal of all used vials, biological equipment, and any unused diluted vaccine. This ensures full compliance with environmental safety regulations and prevents accidental cross-contamination within the facility.
The integrity of a live attenuated vaccine is entirely dependent on the stability of its thermal environment. We have established rigorous storage parameters to guarantee the biological viability of every shipment.
Strict Thermal Thresholds: To preserve the delicate structural integrity of the GD strain, the lyophilized vials must be consistently stored in a dark environment at temperatures below -15℃. This deep-freeze requirement effectively halts biological degradation.
Extended Shelf Life: When maintained under these precise cold chain conditions, the product boasts a highly reliable 12-month shelf life. This extended duration provides commercial distributors and large-scale farms with the confidence to maintain adequate strategic reserves without fear of premature expiration.
Quality Assurance Guarantee: The clear, uncompromising storage guidelines ensure that from the moment the product leaves our manufacturing facility to the moment it is reconstituted in the field, the virus titer remains at its peak potency, delivering guaranteed preventative results.
Partnering with a globally recognized manufacturer ensures that your agricultural enterprise benefits from unparalleled quality control, consistent availability, and deep industry expertise.
Premium Manufacturing Standards: Produced by Qingdao Vland Animal Health Group Co., Ltd., this vaccine is formulated within state-of-the-art, GMP-certified facilities. Every single production phase is subjected to exhaustive internal auditing to ensure absolute purity and consistency.
Uninterrupted Commercial Supply: We possess the expansive manufacturing capacity required to fulfill massive volume orders. Our robust supply chain logistics ensure that regional distributors and large farming conglomerates receive their critical biological assets exactly when seasonal demands surge.
Dedicated Technical Partnership: Beyond simply delivering a product, we provide our commercial partners with access to elite veterinary technical support. Our experts assist with optimizing field administration protocols, auditing cold chain logistics, and developing comprehensive, long-term flock health strategies.
As a premier manufacturer and global supplier of advanced veterinary solutions, we understand the critical nature of biological asset protection in large-scale agricultural operations. Our commitment to operational excellence extends far beyond the vial.
Uncompromising Quality Control: Every batch undergoes rigorous internal auditing in state-of-the-art facilities to ensure maximum viral titer stability and absolute purity before it is approved for commercial distribution.
Robust Supply Chain Management: We maintain extensive production capabilities, ensuring that our commercial partners receive uninterrupted, high-volume deliveries exactly when seasonal breeding demands reach their peak.
Expert Veterinary Support: Our dedicated team of animal health specialists provides comprehensive guidance on cold chain logistics, dilution protocols, and optimal administration techniques to maximize your operational success and flock yield.
Below are professional insights into the most common inquiries regarding the application, storage, and biological mechanics of this preventative solution.
Q: Why is this specific vaccine strictly prohibited for direct use in newly hatched goslings?
A: Direct administration to goslings can cause adverse biological reactions due to their highly underdeveloped immune systems. The GD strain is specifically attenuated to safely stimulate high antibody production in mature breeder geese, which then transfer protective passive immunity directly to the yolk, ensuring the hatchlings are born protected.
Q: What is the exact protocol if the diluted vaccine is not fully consumed within the 4-hour window?
A: Any reconstituted vaccine exceeding the 4-hour timeframe must be immediately discarded following strict biohazard disposal protocols. The biological viability of the live attenuated strain degrades rapidly once in a liquid state, rendering it completely ineffective for disease prevention after this specific window.
Q: How does the physical structure of the lyophilized mass impact field preparation?
A: The vaccine is engineered as a spongy loose mass that detaches easily from the vial wall. This maximizes the surface area exposed to the physiological saline, resulting in instantaneous and complete dissolution. This prevents needle clogging and drastically speeds up preparation time for large flocks.
Q: Can the maternal immunity period be extended beyond the 270-day post-vaccination mark?
A: The clinically proven window for robust maternal antibody transfer is strictly between 21 and 270 days post-vaccination. Eggs laid outside this specific timeframe will not contain sufficient antibody titers to protect the resulting hatchlings, necessitating a strict adherence to the pre-lay vaccination schedule.
Q: What are the critical cold chain requirements for bulk storage and transport?
A: To maintain the minimum virus titer of ≥10 3.0 ELD 50 per dose, the lyophilized vials must be strictly maintained at or below -15℃ in a dark environment. Any deviation from this thermal threshold during transit or storage can permanently compromise the vaccine's structural integrity and overall efficacy.
To be used only under veterinary supervision.
